Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 18, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,423,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,587 pence per share; lowest price paid was 1,574.50 pence per share.
- Treasury Holdings (Settled): 500,236,912 shares (9.32% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,518,912 shares (10.37% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,867,139,881 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,423,000 shares. Consequently, the percentage of shares held in Treasury increased to 9.32% of issued capital and 10.37% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (500,236,912 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights, noting that 10.37% of voting rights are held in Treasury including unsettled shares.
- Check the denominator for shareholder notification thresholds under FCA rules, which is 4,867,139,881 shares.
- Review the price paid (1,574.50 to 1,587 pence) against the market price on October 18, 2013.